semaglutide mastery course
Unit 10 of 12

regulatory landscape and compounding

FDA approvals, compounding controversy, salt form issues, and global access

regulatory landscape and compounding

Semaglutide sits at the center of one of the most contentious regulatory battles in modern pharmaceutical history. The FDA approval pathway spanned diabetes (Ozempic, 2017), obesity (Wegovy, 2021), and cardiovascular risk reduction (2024), while compounding pharmacies exploited shortage designations to produce versions outside Novo Nordisk's patent umbrella. The salt form question -- whether semaglutide sodium qualifies as the same active ingredient -- became the legal fulcrum.

The paid sections dig into the full 2017-2026 FDA milestone timeline, the 503A vs 503B compounding distinction, the salt-form litigation that drove the shortage delisting, and how international pricing and generic timelines diverge from the US landscape.

Interactive Visualization

trace the timeline of FDA approvals, shortage declarations, compounding enforcement actions, and key legal decisions.

FDA approval and compounding enforcement timeline
2017
first FDA approval (Ozempic for T2D) -- expanded to 5 distinct indications across diabetes, obesity, cardiovascular, kidney, and liver disease by 2025
520+
adverse events reported to FDA from compounded semaglutide products -- salt form confusion and potency variability are primary drivers
$900-1,400
monthly list price for branded semaglutide in the US vs $100-400 for compounded versions during the shortage era
early 2030s
estimated first patent expiry -- complex peptide manufacturing with fatty acid conjugation may further delay biosimilar entry even after patents lapse
shortage delisting impact. The FDA removed semaglutide from the drug shortage list in February 2025, ending the legal basis for most compounding. This disrupted access for millions of patients using compounded versions at $100-400/month, forcing transitions to branded products at $900-1,400/month or discontinuation entirely. The salt-form distinction (semaglutide base vs semaglutide sodium) became the central legal argument in enforcement actions.

key terms for this unit

5 503A compounding regulatory
Allows licensed pharmacies to compound patient-specific prescriptions when a commercially available product does not meet the patient's needs. Requires an individual prescription and a valid clinical reason (e.g., allergy to an excipient, need for a specific dose not commercially available).
5 503B outsourcing facility regulatory
Allows production of compounded drugs without patient-specific prescriptions, subject to FDA oversight and current good manufacturing practice (cGMP) requirements. These facilities can produce larger batches for office use, but face more stringent quality standards than 503A pharmacies.
S salt form equivalence pharmaceutical chemistry
The FDA ruled that semaglutide sodium and semaglutide acetate are not the same drug substance as semaglutide base. The counterion (sodium, acetate) adds molecular weight, meaning labeled potency differs from actual peptide content. This distinction drove 5-20x overdoses and became the legal fulcrum for enforcement.
A accelerated approval FDA pathway
An FDA pathway allowing approval based on surrogate endpoints (like liver histology) that are reasonably likely to predict clinical benefit. Semaglutide's MASH approval (August 2025) used this pathway, requiring confirmatory trials to verify that MASH resolution translates to reduced liver events.
A ANDA (abbreviated new drug application) regulatory pathway
The pathway for generic drug approval, requiring demonstration of bioequivalence to the reference product. For semaglutide, the complexity of manufacturing a chemically modified peptide with C18 fatty acid conjugation means generic/biosimilar entry may be delayed well beyond patent expiry in the early 2030s.